Risedronate to Prevent Bone Loss After Sleeve Gastrectomy: Study Design and Feasibility Report of a Pilot Randomized Controlled Trial

Ashlyn A Swafford, Jamy D Ard, Daniel P Beavers, Peri C Gearren, Adolfo Z Fernandez, Sherri A Ford, Katelyn A Greene, Daniel E Kammire, Beverly A Nesbit, Kylie K Reed, Ashley A Weaver, Kristen M Beavers, Ashlyn A Swafford, Jamy D Ard, Daniel P Beavers, Peri C Gearren, Adolfo Z Fernandez, Sherri A Ford, Katelyn A Greene, Daniel E Kammire, Beverly A Nesbit, Kylie K Reed, Ashley A Weaver, Kristen M Beavers

Abstract

Mounting evidence implicates bariatric surgery as a cause of increased skeletal fragility and fracture risk. Bisphosphonate therapy reduces osteoporotic fracture risk and may be effective in minimizing bone loss associated with bariatric surgery. The main objective of this pilot randomized controlled trial (RCT; Clinical Trial No. NCT03411902) was to determine the feasibility of recruiting, treating, and following 24 older patients who had undergone sleeve gastrectomy in a 6 month RCT examining the efficacy of 150-mg once-monthly risedronate (versus placebo) in the prevention of surgical weight-loss-associated bone loss. Feasibility was defined as: (i) >30% recruitment yield, (ii) >80% retention, (iii) >80% pills taken, (iv) <20% adverse events (AEs), and (v) >80% participant satisfaction. Study recruitment occurred over 17 months. Seventy participants were referred, with 24 randomized (34% yield) to risedronate (n = 11) or placebo (n = 13). Average age was 56 ± 7 years, 83% were female (63% postmenopausal), and 21% were black. The risedronate group had a higher baseline BMI than the placebo group (48.1 ± 7.2 versus 41.9 ± 3.8 kg/m2). The 10-year fracture risk was low (6.0% major osteoporotic fracture, 0.4% hip fracture); however, three individuals (12.5%, all risedronate group) were osteopenic at baseline. Twenty-one participants returned for 6-month follow-up testing (88% retention) with all (n = 3) loss to follow-up occurring in the risedronate group. Average number of pills taken among completers was 5.9 ± 0.4 and 6.0 ± 0.0 in the risedronate and placebo groups, respectively (p = 0.21), with active participants taking >80% of allotted pills. Five AEs (3.7% AE rate) were reported; one definitely related, four not related, and none serious. All participants reported high satisfaction with participation in the study. Use of bisphosphonates as a novel therapeutic to preserve bone density in patients who had undergone a sleeve gastrectomy appears feasible and well-tolerated. Knowledge gained from this pilot RCT will be used to inform the design of an appropriately powered trial.

Clinical trial registration: https://ichgcp.net/clinical-trials-registry/NCT03411902. Weight Loss With Risedronate for Bone Health. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

Keywords: ANTIRESORPTIVES; BONE QUANTITATIVE COMPUTED TOMOGRAPHY; CLINICAL TRIALS; DXA; FRACTURE PREVENTION.

© 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

Figures

Fig 1
Fig 1
Weight Loss With Risedronate for Bone Health study flow diagram. FRAX = Fracture risk assessment tool; SG = sleeve gastrectomy; WMC = Weight Management Center.
Fig 2
Fig 2
(A) Exemplar hip volumetric BMD analysis using computed tomography X‐ray absorptiometry hip module. (B) Lumbar spine analysis of volumetric BMD using three‐dimensional spine module. (C) Cortical thickness analysis of femoral neck using the Bone Investigational Toolkit software (Mindways Software, Austin, TX, USA).
Fig 3
Fig 3
Weight Loss With Risedronate for Bone Health study CONSORT (Consolidated Standards of Reporting Trials) diagram. SG = Sleeve gastrectomy.

References

    1. American Society for Metabolic and Bariatric Surgery. Estimate of bariatric surgery numbers, 2011–2018 [Internet]. 2020. [cited 2020 Apr 17]. Available from:
    1. Tian Z, Fan X‐T, Li S‐Z, Zhai T, Dong J. Changes in bone metabolism after sleeve gastrectomy versus gastric bypass: a meta‐analysis. Obes Surg. 2020. Jan;30(1):77–86.
    1. Jaruvongvanich V, Vantanasiri K, Upala S, Ungprasert P. Changes in bone mineral density and bone metabolism after sleeve gastrectomy: a systematic review and meta‐analysis. Surg Obes Relat Dis. 2019. Jun 18;15(8):1252–60.
    1. Rodríguez‐Carmona Y, López‐Alavez FJ, González‐Garay AG, Solís‐Galicia C, Meléndez G, Serralde‐Zúñiga AE. Bone mineral density after bariatric surgery. A systematic review. Int J Surg. 2014;12(9):976–82.
    1. Yu EW, Bouxsein ML, Putman MS, et al. Two‐year changes in bone density after Roux‐en‐Y gastric bypass surgery. J Clin Endocrinol Metab. 2015. Apr;100(4):1452–9.
    1. Stein EM, Carrelli A, Young P, et al. Bariatric surgery results in cortical bone loss. J Clin Endocrinol Metab. 2013. Feb;98(2):541–9.
    1. Stein EM, Silverberg SJ. Bone loss after bariatric surgery: causes, consequences and management. Lancet Diabetes Endocrinol. 2014. Feb;2(2):165–74.
    1. Ablett AD, Boyle BR, Avenell A. Fractures in adults after weight loss from bariatric surgery and weight management programs for obesity: systematic review and meta‐analysis. Obes Surg. 2019. Apr;29(4):1327–42.
    1. Zhang Q, Chen Y, Li J, et al. A meta‐analysis of the effects of bariatric surgery on fracture risk. Obes Rev. 2018;19(5):728–36.
    1. Fashandi AZ, Mehaffey JH, Hawkins RB, Schirmer B, Hallowell PT. Bariatric surgery increases risk of bone fracture. Surg Endosc. 2018;32(6):2650–5.
    1. Javanainen M, Pekkarinen T, Mustonen H, Scheinin T, Leivonen M. Two‐year nutrition data in terms of vitamin D, vitamin B12, and albumin after bariatric surgery and long‐term fracture data compared with conservatively treated obese patients: a retrospective cohort study. Obes Surg. 2018. Sep 1;28(9):2968–75.
    1. Cranney A, Tugwell P, Adachi J, et al. Meta‐analyses of therapies for postmenopausal osteoporosis. III. Meta‐analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002. Aug;23(4):517–23.
    1. Lanza FL, Hunt RH, Thomson AB, Provenza JM, Blank MA. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology. 2000. Sep;119(3):631–8.
    1. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008. Sep;83(9):1032–45.
    1. Yu EW. Bone metabolism after bariatric surgery. J Bone Miner Res. 2014. Jul;29(7):1507–18.
    1. Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures – 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 2020. Feb 1;16(2):175–247.
    1. American Society for Metabolic and Bariatric Surgery .. Who is a Candidate for Bariatric Surgery? [Internet] 2018. [cited 2019 Jul 3]. Available from:
    1. Watts NB, Lewiecki EM, Miller PD, Baim S. National Osteoporosis Foundation 2008 Clinician's guide to prevention and treatment of osteoporosis and the World Health Organization fracture risk assessment tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom. 2008. Dec;11(4):473–7.
    1. Norwich Pharmaceuticals, Inc. Highlights of prescribing information: Actonel (risedronate sodium) tablets [Internet]. Warner Chilcott (US), LLC. 2015. [cited 2020 Feb 18]. Available from:
    1. Paramasivan S, Rogers CA, Welbourn R, et al. Enabling recruitment success in bariatric surgical trials: pilot phase of the By‐Band‐Sleeve study. Int J Obes (Lond). 2017. Nov;41(11):1654–61.
    1. Abshire M, Dinglas VD, Cajita MI, Eakin MN, Needham DM, Himmelfarb CD. Participant retention practices in longitudinal clinical research studies with high retention rates. BMC Med Res Methodol. 2017;17(1):30.
    1. Bowen DJ, Kreuter M, Spring B, et al. How we design feasibility studies. Am J Prev Med. 2009. May;36(5):452–7.
    1. Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med. 2003. Apr 10;348(15):1503–4.
    1. Beavers KM, Walkup MP, Weaver AA, et al. Effect of exercise modality during weight loss on bone health in older adults with obesity and cardiovascular disease or metabolic syndrome: a randomized controlled trial. J. Bone Miner. Res. 2018. Dec;33(12):2140–9.
    1. Shepherd J, Ng B, Sommer M, Heymsfield SB. Body composition by DXA. Bone. 2017. Nov;104:101–5.
    1. Kelleher JL, Beavers DP, Henderson RM, et al. Weighted vest use during dietary weight loss on bone health in older adults with obesity. J Osteoporos Phys Act. 2017;5(4):210.
    1. World Health Organization . Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129.
    1. Jurgensen JA, Reidt W, Kellogg T, Mundi M, Shah M, Collazo Clavell ML. Impact of patient attrition from bariatric surgery practice on clinical outcomes. Obes Surg. 2019. Feb 1;29(2):579–84.
    1. World Health Organization . Adherence to long‐term therapies: evidence for action [Internet]. 2003 [cited 2020. Mar 12]. Available from:
    1. Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin. 2006;22(12):2383–91.
    1. Moro‐Álvarez MJ, Díaz‐Curiel M. Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis. Clin Interv Aging. 2008. Jun;3(2):227–32.
    1. Ko B‐J, Myung SK, Cho K‐H, et al. Relationship between bariatric surgery and bone mineral density: a meta‐analysis. Obes Surg. 2016;26(7):1414–21.
    1. Liu C, Wu D, Zhang J‐F, et al. Changes in bone metabolism in morbidly obese patients after bariatric surgery: a meta‐analysis. Obes Surg. 2016. Jan;26(1):91–7.
    1. Paccou J, Martignène N, Lespessailles E, et al. Gastric Bypass But Not Sleeve Gastrectomy Increases Risk of Major Osteoporotic Fracture: French Population‐Based Cohort Study. J Bone Miner Res. 2020;35(8):1415–1423. 10.1002/jbmr.4012.
    1. Muschitz C, Kocijan R, Haschka J, et al. The impact of vitamin D, calcium, protein supplementation, and physical exercise on bone metabolism after bariatric surgery: the BABS study. J Bone Miner Res. 2016. Mar 1;31(3):672–82.
    1. Murai IH, Roschel H, Dantas WS, et al. Exercise mitigates bone loss in women with severe obesity after Roux‐en‐Y gastric bypass: a randomized controlled trial. J Clin Endocrinol Metab. 2019. Oct 1;104(10):4639–50.
    1. Campanha‐Versiani L, Pereira DAG, Ribeiro‐Samora GA, et al. The effect of a muscle weight‐bearing and aerobic exercise program on the body composition, muscular strength, biochemical markers, and bone mass of obese patients who have undergone gastric bypass surgery. Obes Surg. 2017;27(8):2129–37.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe